Loading
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Previous close
$2.54
+$0.05 · +2.01%
After-hours
$2.54
$0.00 · 0.00%
Sep 14, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Day range
Current $2.54
52-week range
Current $2.54
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
12
Overpriced
Sentiment
53
Mixed
Risk
58
Elevated Risk
Momentum
39
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Day range
Current $2.54
52-week range
Current $2.54
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 8K USD | 8K USD | 170K USD | 11.07M USD | — |
| Cost of goods sold | 574K USD | 903K USD | 1.02M USD | 968K USD | 895K USD |
| Gross profit | −566K USD | −895K USD | −848K USD | 10.1M USD | −895K USD |
| Research and development | 19.85M USD | 19M USD | 12.77M USD | 9.08M USD | 6.32M USD |
| Selling, general, and administrative | 13.37M USD | 12.71M USD | 11.57M USD | 5M USD | 8.29M USD |
| Operating expenses | 32.65M USD | 30.8M USD | 23.32M USD | 13.11M USD | 13.72M USD |
| Interest income | 1.07M USD | 1.46M USD | 244K USD | — | — |
| Interest expense | — | — | 3.97M USD | 1.41M USD | 1.82M USD |
| Depreciation and amortization | 574K USD | 903K USD | 1.02M USD | 968K USD | 895K USD |
| Operating income | −33.21M USD | −31.7M USD | −24.17M USD | −3.01M USD | −14.61M USD |
| Net income | −32.15M USD | −29.87M USD | −28.3M USD | −5.21M USD | −17.8M USD |
Company facts updated Sep 15, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$17.33
582.28% upsideLimited analyst sample: 3 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
